Literature DB >> 3275523

A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts.

W K Bickel1, M L Stitzer, G E Bigelow, I A Liebson, D R Jasinski, R E Johnson.   

Abstract

The efficacy of buprenorphine and methadone was compared in the outpatient detoxification of heroin addicts. Forty-five patients were randomized to receive either sublingual buprenorphine or oral methadone under double-dummy and double-blind conditions to study the pharmacology of buprenorphine in a 90-day detoxification protocol. The patients were administered either 2 mg buprenorphine or 30 mg methadone for 3 weeks followed by 4 weeks of dose reductions and 6 weeks of placebo medication. No significant between-group differences were seen on measures of treatment retention, drug use, or symptom report. During the hydromorphone challenge, methadone attenuated opioid effects to a greater extent than did buprenorphine on both physiologic (pupil constriction) and self-report measures. However, this did not result in greater abuse of illicit opioid drugs by subjects taking buprenorphine. The results of this clinical trial indicated that buprenorphine was acceptable to patients and as effective as methadone in the detoxification treatment of heroin addicts.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3275523     DOI: 10.1038/clpt.1988.13

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  54 in total

1.  Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films.

Authors:  E C Strain; J A Harrison; G E Bigelow
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 2.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

3.  Comparison of methadone and buprenorphine for opiate detoxification (LEEDS trial): a randomised controlled trial.

Authors:  Nat M J Wright; Laura Sheard; Clive E Adams; Bruno J Rushforth; Wendy Harrison; Nicole Bound; Roger Hart; Charlotte N E Tompkins
Journal:  Br J Gen Pract       Date:  2011-12       Impact factor: 5.386

4.  Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.

Authors:  Sandra D Comer; Warren K Bickel; Richard Yi; Harriet de Wit; Stephen T Higgins; Galen R Wenger; Chris-Ellyn Johanson; Mary Jeanne Kreek
Journal:  Behav Pharmacol       Date:  2010-07       Impact factor: 2.293

5.  Association of race and ethnicity with withdrawal symptoms, attrition, opioid use, and side-effects during buprenorphine therapy.

Authors:  E Sherwood Brown; Carlos Tirado; Abu Minhajuddin; Maureen Hillhouse; Bryon Adinoff; Walter Ling; Geetha Doraimani; Christie Thomas
Journal:  J Ethn Subst Abuse       Date:  2010       Impact factor: 1.507

6.  Substance abuse treatment organizations as mediators of social policy: slowing the adoption of a congressionally approved medication.

Authors:  Stanley S Wallack; Cindy Parks Thomas; Timothy C Martin; Jon Chilingerian; Sharon Reif
Journal:  J Behav Health Serv Res       Date:  2008-07-31       Impact factor: 1.505

7.  Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.

Authors:  Debra S Harris; John E Mendelson; Emil T Lin; Robert A Upton; Reese T Jones
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

8.  Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users.

Authors:  E C Strain; M L Stitzer; I A Liebson; G E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

9.  Buprenorphine tapering schedule and illicit opioid use.

Authors:  Walter Ling; Maureen Hillhouse; Catherine Domier; Geetha Doraimani; Jeremy Hunter; Christie Thomas; Jessica Jenkins; Albert Hasson; Jeffrey Annon; Andrew Saxon; Jeffrey Selzer; Joshua Boverman; Richard Bilangi
Journal:  Addiction       Date:  2009-02       Impact factor: 6.526

Review 10.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.